Prostate brachytherapy: Indications and outcomes;Curiethérapie exclusive du cancer de la prostate par implants permanents: Indications et résultats. Revue du CC-AFU

Progres en Urologie

Volumn 23, Issue 6, 2013, Pages 378-385

  Hennequin, C ^a   Cormier, L ^b   Richaud, P ^c   Bastide, C ^d   Beuzeboc, P ^e   Fromont, G ^f   Mongiat Artus, P ^a   Peyromaure, M ^g   Ploussard, G ^a   Renard Penna, R ^h   Rozet, F ⁱ   Soulie M ^j   Salomon, L ^k  

^a SAINT LOUIS HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c centre Bergonié   (France)

^d HÔPITAL NORD   (France)

^e INSTITUT CURIE   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g Hôpital Saint Louis ^*  (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ INSTITUT MUTUALISTE MONTSOURIS   (France)

^j CHU RANGUEIL   (France)

^k HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Brachytherapy; Prostate cancer

Indexed keywords

BRACHYTHERAPY; HUMAN; MALE; PROSTATE TUMOR; SHORT SURVEY; TREATMENT OUTCOME;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84876965347     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.12.006     Document Type: Short Survey

References (66)

1. Giberti C., Chiono L., Gallo F., et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009, 27:607-612.
2. Peinemann F., Grouven U., Hemkens L.G., et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 2011, CD008871.
3. Crook J.M., Gomez-Iturriaga A., Wallace K., et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2011, 29:362-368.
4. Buron C., Le Vu B., Cosset J.M., et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys 2007, 67:812-822.
5. D'Amico A., Whiington R., Malkowicz B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or intersticial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
6. Salomon L., Azria D., Bastide C., et al. Recommendations Onco-Urology 2010: prostate cancer. Prog Urol 2010, 20(Suppl. 4):S217-S251.
7. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:1487-1493.
8. Crook J., Gillan C., Yeung I., et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007, 69:426-433.
9. Henry A.M., Al-Qaisieh B., Gould K., et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys 2010, 76:50-56.
10. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008, 179:S20-S24.
11. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
12. Zhou E.H., Ellis R.J., Cherullo E., et al. Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys 2009, 73:15-23.
13. Kupelian P., Potters L., Khuntia D., et al. Radical prostatectomy, extrenal beal radiotherapy<72Gy, extrenal beam radiotherapy≥72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:25-33.
14. Grimm P., Billiet I., Bostwick D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012, 109(Suppl. 1):22-29.
15. Peinemann F., Grouven U., Bartel C., et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 2011, 60:881-893.
16. Frank S.J., Levy L.B., Kuban D.A., et al. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol 2009, 181:1658-1663. [Discussion 1663-4].
17. Frank S.J., Levy L.B., van Vulpen M., et al. Outcomes after prostate brachytherapy are even better than predicted. Cancer 2012, 118:839-847.
18. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001, 50:605-614.
19. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998, 41:101-108.
20. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
21. Stone N.N., Stock R.G., Cesaretti J.A., et al. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010, 76:355-360.
22. Chen A.B., D'Amico A.V., Neville B.A., et al. Provider case volume and outcomes following prostate brachytherapy. J Urol 2009, 181:113-118. [Discussion 118].
23. Merrick G.S., Wallner K.E., Butler W.M., et al. Brachytherapy in men aged
24. Burri R.J., Ho A.Y., Forsythe K., et al. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:1315-1321.
25. Cosset J.M., Flam T., Thiounn N., et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients. Int J Radiat Oncol Biol Phys 2008, 71:1042-1048.
26. Munro N.P., Al-Qaisieh B., Bownes P., et al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. Radiother Oncol 2010, 96:34-37.
27. Vassil A.D., Murphy E.S., Reddy C.A., et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010, 76:1251-1257.
28. Lee L.N., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:444-452.
29. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:669-677.
30. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000, 18:1187-1192.
31. D'Amico A.V., Moran B.J., Braccioforte M.H., et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009, 27:3923-3928.
32. Keyes M., Miller S., Moravan V., et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys 2009, 75:649-655.
33. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 47:121-128.
34. Miller N.L., Theodorescu D. Health-related quality of life after prostate brachytherapy. BJU Int 2004, 94:487-491.
35. Kao J., Stone N.N., Lavaf A., et al. (125)I monotherapy using D90 implant doses of 180Gy or greater. Int J Radiat Oncol Biol Phys 2008, 70:96-101.
36. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catherization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys 2002, 52:712-719.
37. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:453-460.
38. Lee N., Wuu C.S., Brody R., et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 48:1457-1460.
39. Martens C., Pond G., Webster D., et al. Relationship of the international prostate symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006, 5:9-13.
40. Emara A.M., Chadwick E., Nobes J.P., et al. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU Int 2010, 109:994-1000.
41. Gutman S., Merrick G.S., Butler W.M., et al. Severity categories of the international prostate symptom score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 2006, 97:62-68.
42. Ash D., Bottomley D., Al-Qaisieh B., et al. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 2007, 84:135-139.
43. Chen R.C., Clark J.A., Talcott J.A. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009, 27:3916-3922.
44. Stone N.N., Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007, 69:338-342.
45. Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002, 60:650-655.
46. Elshaikh M.A., Ulchaker J.C., Reddy C.A., et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005, 62:164-169.
47. Colson M.H., Lechevallier E., Rambeaud J.J., et al. Sexuality and prostate cancer. Prog Urol 2012, 22(Suppl. 2):S72-S92.
48. Alemozaffar M., Regan M.M., Cooperberg M.R., et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011, 306:1205-1214.
49. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001, 50:1235-1242.
50. Delaunay B., Delannes M., Salloum A., et al. Orgasm after curietherapy with permanent iodine-125 radioimplants for localized prostate cancer. Prog Urol 2011, 21:932-939.
51. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
52. Pardo Y., Guedea F., Aguilo F., et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010, 28:4687-4696.
53. Malcolm J.B., Fabrizio M.D., Barone B.B., et al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010, 183:1822-1828.
54. Pahlajani G., Raina R., Jones J.S., et al. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 2010, 106:1524-1527.
55. Miller D.C., Sanda M.G., Dunn R.L., et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005, 23:2772-2780.
56. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002, 20:557-566.
57. Krupski T., Petroni G.R., Bissonette E.A., et al. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000, 55:736-742.
58. Litwin M.S., Gore J.L., Kwan L., et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109:2239-2247.
59. Mehta S.S., Lubeck D.P., Pasta D.J., et al. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 2003, 170:1931-1933.
60. Mundy A.R., Andrich D.E. Urorectal fistulae following the treatment of prostate cancer. BJU Int 2011, 107:1298-1303.
61. Hinnen K.A., Schaapveld M., van Vulpen M., et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 2011, 29:4510-4515.
62. Nguyen P.L., Gu X., Lipsitz S.R., et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011, 29:1517-1524.
63. Jabbari S., Weinberg V.K., Shinohara K., et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010, 76:36-42.
64. Zelefsky M.J., Yamada Y., Pei X., et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011, 77:986-990.
65. Zebentout O., Apardian R., Beaulieu L., et al. Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: the Hôtel-Dieu of Quebec experience. Cancer Radiother 2010, 14:183-188.
66. Taira A.V., Merrick G.S., Galbreath R.W., et al. Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:639-648.